Register Login

Insmed Inc (INSM)

  • Event
  • May 23, 2022, 12:05 UTC

(10% Negative) INSMED INCORPORATED (INSM) Announces Delay in point Trials for launching new product Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 9:41 p.m.

    📋 INSMED INCORPORATED (INSM) - Clinical Trial Update

    Filing Date: 2022-05-23

    Accepted: 2022-05-23 08:05:25

    Event Type: Clinical Trial Update

    Event Details:

    Insmed Inc (INSM) Announces Clinical Trial Update Insmed Inc (INSM) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: point, talent
    • Diseases/Conditions: launching new product, all of Insmed’s global commercial functions
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process
    • Collaboration: ARIKAYCE
      • targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com. Forward-looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Insmed Inc
    • CIK: 0001104506
    • Ticker Symbol: INSM
    • Period End Date: 2022-05-23
    • Document Type: 8-K

Search

News categories